Understanding Sedative and Pain Medication Levels in Children on ECMO
This study is looking at how the body processes common sedatives and pain medications like dexmedetomidine, fentanyl, and morphine in children (ages newborn to 17 years old) who are on ECMO (Extracorporeal Membrane Oxygenation). ECMO is a life support system that helps the heart and lungs. Researchers want to measure the levels of these drugs in the blood over time to better understand how they work in children on ECMO. This information can help doctors give the right doses to keep children comfortable and safe. The study aims to enroll 20 participants and is currently observational, meaning it watches what happens without giving new treatments. The study's status is currently unclear.
- Study design
- This is an observational study involving up to 20 participants, looking at how the body processes certain medications.
- What's involved
- Participants will have blood samples taken at specific times (baseline, 30, 60, 120 minutes, 4, 6, 12 hours after changes in medication, and after the medication is stopped) to measure drug levels.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed throughout the duration of their sedation management with the study drugs, and for up to 4 hours after the drug is stopped.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support
At a glance
Conditions
NCT03593408
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Boston Children's Hospital
Boston, Massachusettsno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Viviane Nasr, MD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in plasma concentrations of dexmedetomidineThroughout the duration of sedation management with dexmedetomidine at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped
- change in plasma concentrations of fentanylThroughout the duration of sedation management with fentanyl at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped
- change in plasma concentrations of morphineThroughout the duration of sedation management with morphine at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped
- change in plasma concentrations of midazolamThroughout the duration of sedation management with midazolam at baseline, 30, 60, 120 minutes and then at 4, 6, 12 hours after each bolus or change in infusion and then at 30,60, 90, 120, 240minutes and 4 hours after the drug is stopped